Diagnosis of Crohn's disease and ulcerative colitis using the microbiomeOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether the gut microbiome could be used to differentiate and diagnose Crohn's disease (CD) and ulcerative colitis (UC), the two major forms of inflammatory bowel disease (IBD). Researchers compared the abundance and composition of gut microbiota across disease states and looked for specific biomarkers linked to disease activity. The work also examined how microbial diversity changed as disease progressed through different stages.
Who was studied?
The abstract describes patients with IBD, split into CD and UC groups, compared against healthy controls (HC). Specific numbers of participants, demographics, and enrollment details are not given in the abstract, so the exact cohort size and characteristics cannot be stated. The comparison design (IBD patients versus healthy controls, with CD and UC analyzed separately) is the only population detail confirmed.
What were the most important findings?
Gut microbiome diversity was lower in IBD patients than in healthy controls, and this reduction was significantly more pronounced in CD patients. The researchers identified 68 microbiota members associated with these diseases, 28 linked to CD and 40 linked to UC. Microbial diversity also declined further as disease progressed through more advanced stages. Specific taxa tracked with severity: Alistipes shahii and Pseudodesulfovibrio aespoeensis abundances were negatively correlated with CD severity, while Polynucleobacter wianus abundance was positively associated with it.
What are the greatest implications of this study?
These findings suggest the gut microbiome could serve as a diagnostic tool to distinguish CD from UC, addressing a clinically difficult differential diagnosis. Identifying species whose abundance correlates with disease severity points toward potential microbial biomarkers for monitoring disease activity and staging. Such biomarkers could support more precise, long-term treatment planning for IBD patients.